Roche Succeeds In Changing EMA Ruling On Avastin
This article was originally published in The Pink Sheet Daily
Executive Summary
The Committee for Medicinal Products for Human Use has reversed its previous rejection and is granting an indication for treatment of first-line breast cancer in combination with capecitabine.